SunTrust Banks Analysts Give American Renal Associates (ARA) a $20.00 Price Target

SunTrust Banks set a $20.00 price objective on American Renal Associates (NYSE:ARA) in a research note issued to investors on Thursday morning. The firm currently has a buy rating on the stock. SunTrust Banks also issued estimates for American Renal Associates’ Q4 2017 earnings at $0.15 EPS, FY2017 earnings at $0.56 EPS, Q1 2018 earnings at $0.10 EPS, Q2 2018 earnings at $0.18 EPS, Q3 2018 earnings at $0.19 EPS, Q4 2018 earnings at $0.22 EPS, FY2018 earnings at $0.69 EPS, Q1 2019 earnings at $0.15 EPS, Q2 2019 earnings at $0.21 EPS, Q3 2019 earnings at $0.23 EPS and FY2019 earnings at $0.82 EPS.

A number of other brokerages also recently commented on ARA. Zacks Investment Research raised shares of American Renal Associates from a hold rating to a buy rating and set a $13.00 price objective for the company in a research note on Thursday, November 16th. Leerink Swann reissued an outperform rating and issued a $17.00 price objective (down previously from $22.00) on shares of American Renal Associates in a research note on Tuesday, November 21st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $18.25.

Shares of American Renal Associates (NYSE:ARA) opened at $17.05 on Thursday. The company has a debt-to-equity ratio of 3.57, a quick ratio of 1.13 and a current ratio of 1.16. American Renal Associates has a 12 month low of $9.91 and a 12 month high of $23.30. The firm has a market cap of $528.54, a P/E ratio of -51.67, a PEG ratio of 1.49 and a beta of 4.29.

American Renal Associates (NYSE:ARA) last posted its quarterly earnings results on Tuesday, November 14th. The company reported $0.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.03. American Renal Associates had a negative net margin of 2.15% and a positive return on equity of 15.80%. The firm had revenue of $187.71 million during the quarter, compared to the consensus estimate of $194.60 million. During the same quarter in the previous year, the firm posted $0.28 earnings per share. The company’s revenue was down 2.7% on a year-over-year basis. sell-side analysts expect that American Renal Associates will post 0.56 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of American Renal Associates by 11.6% during the first quarter. Vanguard Group Inc. now owns 928,768 shares of the company’s stock valued at $15,678,000 after buying an additional 96,196 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of American Renal Associates by 2.9% during the first quarter. Geode Capital Management LLC now owns 77,726 shares of the company’s stock valued at $1,312,000 after buying an additional 2,180 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of American Renal Associates by 7.1% during the first quarter. Schwab Charles Investment Management Inc. now owns 38,847 shares of the company’s stock valued at $656,000 after buying an additional 2,565 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of American Renal Associates by 21.6% during the first quarter. Bank of America Corp DE now owns 29,837 shares of the company’s stock valued at $504,000 after buying an additional 5,296 shares during the last quarter. Finally, Strs Ohio grew its holdings in shares of American Renal Associates by 12.6% during the second quarter. Strs Ohio now owns 33,000 shares of the company’s stock valued at $612,000 after buying an additional 3,700 shares during the last quarter. 93.27% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “SunTrust Banks Analysts Give American Renal Associates (ARA) a $20.00 Price Target” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/12/25/suntrust-banks-analysts-give-american-renal-associates-ara-a-20-00-price-target.html.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit